Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Core Insights - Verve Therapeutics is making significant progress in its clinical trials for cardiovascular disease treatments, with key data expected in 2025 [1][2][3] Pipeline Updates - Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is anticipated in the second quarter of 2025, with final dose escalation data expected in the second half of 2025 [1][3] - VERVE-102 has shown good tolerability, with no serious adverse events or significant laboratory abnormalities reported [1][3] - Enrollment is ongoing for the Pulse-1 Phase 1b clinical trial of VERVE-201, which targets ANGPTL3 [1][4] Financial Position - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities totaling $524.3 million, providing a cash runway into mid-2027 [1][8] - Collaboration revenue for the fourth quarter of 2024 was$13.1 million, up from $5.1 million in the same quarter of 2023, indicating growth in research services [9] - Research and development expenses for the fourth quarter of 2024 were$55.0 million, compared to $46.8 million in the fourth quarter of 2023 [10] Leadership Changes - Dr. Frederick T. Fiedorek, Chief Medical Officer, will retire effective February 28, 2025, but will continue in an advisory role [2][7] Upcoming Events - Verve Therapeutics will present at the European Atherosclerosis Society Congress from May 4-7, 2025, in Glasgow, UK [5]